Search Results

You are looking at 1 - 3 of 3 items for :

  • Abstract: adrenarche x
  • Abstract: fertility x
  • Abstract: Gender x
  • Abstract: Hypogonadism x
  • Abstract: infertility x
  • Abstract: Kallmann x
  • Abstract: Klinefelter x
  • Abstract: menarche x
  • Abstract: menopause x
  • Abstract: puberty x
  • Abstract: transsexual x
  • Abstract: sperm* x
  • Abstract: ovary x
  • Abstract: follicles x
Clear All Modify Search
Yanling Cai Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China

Search for other papers by Yanling Cai in
Google Scholar
PubMed
Close
,
Yan Yang Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China

Search for other papers by Yan Yang in
Google Scholar
PubMed
Close
,
Xiao Pang Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China

Search for other papers by Xiao Pang in
Google Scholar
PubMed
Close
, and
Suping Li Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China

Search for other papers by Suping Li in
Google Scholar
PubMed
Close

Purpose

The aim was to investigate the effect of radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) on male gonadal function.

Methods

PubMed, Embase, Web of Science, OVID, Scopus, and Wanfang databases were searched up to June 10, 2022, to identify published studies related to RAI and male gonadal function. ReviewManager version 5.4.1 software was used to calculate mean differences (MDs) with 95% CIs.

Results

Initially, 1958 articles were retrieved from the databases, and 6 articles were included in the quantitative analysis. The meta-analysis results showed that follicle-stimulating hormone (FSH) increased when the follow-up duration was ≥12 months after RAI, but the difference was not statistically significant (MD = −2.64, 95% CI = (−5.61, 0.33), P = 0.08). But the results of the subgroup analysis showed that when the follow-up time was ≤6 months, FSH levels were significantly higher after RAI (MD = −7.65, 95% CI = (−13.95, −1.34), P = 0.02). The level of inhibin B was significantly lower at ≥12 months and ≤6 months after RAI (MD = 66.38, 95% CI = (8.39, 124.37), P = 0.02) and (MD = 116.27, 95% CI = (43.56, 188.98), P = 0.002). Additionally, luteinizing hormone (LH) and testosterone have similar results – that is, LH and testosterone levels were higher after RAI, but the difference was not statistically significant (MD = –0.87, 95% CI = (−2.04, 0.30), P = 0.15) and (MD = −1.69, 95% CI (−7.29, 3.90), P = 0.55).

Conclusions

Male gonadal function may be temporarily impaired within 6 months after RAI but may return to normal levels afterward.

Open access
Qiankai Jin Department of Endocrinology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo, China
School of Medicine, Ningbo University, Ningbo, China

Search for other papers by Qiankai Jin in
Google Scholar
PubMed
Close
,
Guoqing Huang Department of Endocrinology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo, China
School of Medicine, Ningbo University, Ningbo, China

Search for other papers by Guoqing Huang in
Google Scholar
PubMed
Close
,
Xiaoqing Tian Department of Endocrinology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo, China
School of Medicine, Ningbo University, Ningbo, China

Search for other papers by Xiaoqing Tian in
Google Scholar
PubMed
Close
,
Yimeng Shu Department of Endocrinology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo, China
School of Medicine, Ningbo University, Ningbo, China

Search for other papers by Yimeng Shu in
Google Scholar
PubMed
Close
,
Ximisinuer Tusongtuoheti Department of Endocrinology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo, China
School of Medicine, Ningbo University, Ningbo, China

Search for other papers by Ximisinuer Tusongtuoheti in
Google Scholar
PubMed
Close
, and
Yushan Mao Department of Endocrinology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo, China

Search for other papers by Yushan Mao in
Google Scholar
PubMed
Close

Objective

The aim of this study was to elaborate the link of thyroid hormones (THs) and metabolic syndrome (MetS) in a Chinese euthyroid employee population with MetS component(s).

Methods

An annual health checkup was performed on employees in 2019. Anthropometric parameters, metabolic parameters, and thyroid function were measured. A questionnaire was used in conjunction with Zhenhai Lianhua Hospital database to receive employees' medication records and thyroid surgical history records.

Results

A total of 5486 eligible employees were included; the prevalence of MetS was generally higher in males than in females (38.9 vs. 30.4%, P < 0.001). Among employees with central obesity, hypertriglyceridemia, hyperglycemia, hypertension, and low high-density lipoprotein cholesterol (HDL-C), the prevalence of MetS was 68.8, 63.6, 68.2, 48.8, and 60.0% in males and 72.6, 63.3, 61.3, 42.3, and 42.3% in females, respectively. Logistic regression analysis showed that thyroid-stimulating hormone and free thyroxine (FT4) quartiles had no significant impact on MetS. Free triiodothyronine/free thyroxine (FT3/FT4) and free triiodothyronine (FT3)) quartiles were positively associated with the increased odds ratio (OR) for MetS and dyslipidemia (hypertriglyceridemia and low HDL-C), regardless of gender. In males, FT3 and FT3/FT4 quartiles were positively associated with the OR for central obesity, whereas FT4 quartiles were negatively associated; both FT3 and FT4 quartiles were positively associated with increased OR of hyperglycemia, while similar results were not observed in females. Interaction analysis indicated no significant effect of gender and TH interactions on risk of MetS.

Conclusion

High FT3 and FT3/FT4 were strongly linked with MetS and dyslipidemia in our study, even in the euthyroid individuals. Tighter control of thyroid function was necessary for those with preexisting MetS component(s).

Open access
Zhengrong Jiang Department of Endocrinology, The Second affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Search for other papers by Zhengrong Jiang in
Google Scholar
PubMed
Close
,
Linghong Huang Department of Endocrinology, The Second affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Search for other papers by Linghong Huang in
Google Scholar
PubMed
Close
,
Lijun Chen Department of Endocrinology, The Second affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Search for other papers by Lijun Chen in
Google Scholar
PubMed
Close
,
Jingxiong Zhou Department of Endocrinology, The Second affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Search for other papers by Jingxiong Zhou in
Google Scholar
PubMed
Close
,
Bo Liang Department of Endocrinology, The Second affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Search for other papers by Bo Liang in
Google Scholar
PubMed
Close
,
Xuefeng Bai Department of Endocrinology, The Second affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Search for other papers by Xuefeng Bai in
Google Scholar
PubMed
Close
,
Lizhen Wu Department of Endocrinology, The Second affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Search for other papers by Lizhen Wu in
Google Scholar
PubMed
Close
, and
Huibin Huang Department of Endocrinology, The Second affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Search for other papers by Huibin Huang in
Google Scholar
PubMed
Close

Background

Graves’ disease is a common autoimmune disease. Cytokines and their signalling pathways play a major part in the pathogenesis of Graves’ disease; however, the underlying mechanism needs to be clarified.

Aims

The aim of this study was to explore whether circular RNAs participate in the immunological pathology of Graves’ disease via cytokine-related signalling pathways.

Methods

Bioinformatics analysis was performed to identify differentially expressed circular RNAs and their targets and associated pathways. A total of three patients with Graves’ disease and three sex- and age-matched healthy controls were enrolled for validation with microarray analysis and real-time quantitative PCR (qPCR). An additional 24 patients with Graves’ disease and 24 gender- and age-matched controls were included for validation by real-time fluorescent qPCR. Flow cytometry and CCK8 assays were used to detect the apoptotic and proliferative levels of Jurkat cells (T lymphocytes) with the silenced expression of circRNA. ELISA was performed to detect the growth and apoptosis-related proteins. The competition mechanism of endogenous RNA was explored by real-time fluorescence qPCR.

Results

A total of 366 significantly differentially expressed circular RNAs were identified in the Graves’ disease group compared to healthy controls. The level of hsa_circ_0090364 was elevated in Graves’ disease patients and positively correlated with thyroid-stimulating hormone receptor antibodies. Further analyses suggested that hsa_circ_0090364 may regulate the JAK-STAT pathway via the hsa-miR-378a-3p/IL-6ST/IL21R axis to promote cell growth.

Conclusions

These results provide novel clues into the pathophysiological mechanisms of Graves’ disease and potential targets for drug treatment.

Open access